This expression of SOX10 in the absence of OLIG2 does not occur during glial development40 and may reflect the aberrant dysregulation of the glioma genomic landscape, which is consistent with previous work showing time-specific fate-switching of glioma cells to favor oligodendrocyte-like cells at end stages of tumor progression100. The gene discussed is OLIG2; the disease is glioma.